| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
N-(3-Methoxybenzyl)Palmitamide targets fatty acid amide hydrolase (FAAH), an enzyme responsible for the degradation of endogenous fatty acid amides such as anandamide. FAAH is a serine hydrolase that hydrolyzes fatty acid amides to fatty acids and ethanolamine or corresponding amines, thereby terminating their signaling activities. By inhibiting FAAH, the compound increases the levels of endogenous fatty acid amides, which are involved in the modulation of pain, inflammation, and neuroprotection. This mechanism makes FAAH inhibitors promising therapeutic candidates for pain management, inflammatory conditions, and neurodegenerative disorders. The compound shows high lipophilicity with a LogP of 8.3.
|
|---|---|
| ln Vitro |
In vitro, N-(3-Methoxybenzyl)Palmitamide functions as a potent FAAH inhibitor useful in the research and study of pain, inflammation, and degenerative diseases of the central nervous system. The compound's inhibitory activity against FAAH has been documented in peer-reviewed literature, including studies published in FASEB Journal. The compound demonstrates the ability to counteract toxicity produced by Aβ peptides. As a synthetic macamide analog, it serves as a valuable tool for investigating the endocannabinoid system and fatty acid amide signaling pathways. Its potency and selectivity make it suitable for cellular studies aimed at understanding FAAH biology and developing novel therapeutic strategies for pain and inflammatory disorders.
|
| ln Vivo |
In vivo, N-(3-Methoxybenzyl)Palmitamide has potential applications in the treatment of pain, inflammation, and CNS degenerative disorders based on its FAAH inhibitory activity. FAAH inhibitors have been shown to produce analgesic, anti-inflammatory, and neuroprotective effects in various animal models by elevating endogenous fatty acid amide levels. The compound's structural features, including its long hydrophobic palmitic acid chain and 3-methoxybenzyl moiety, suggest favorable blood-brain barrier penetration. However, detailed in vivo efficacy, pharmacokinetic, and toxicological data for this specific compound require further investigation from primary research publications. It is supplied as a research chemical for preclinical studies.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cellular) assays for N-(3-Methoxybenzyl)Palmitamide involve measuring FAAH inhibition using purified recombinant FAAH enzyme. The assay typically uses a fluorogenic substrate such as arachidonoyl-7-amino-4-methylcoumarin amide (AMC-AA) or oleamide that releases fluorescent AMC upon hydrolysis by FAAH. The enzyme is incubated with varying concentrations of the compound in assay buffer (typically 50 mM Tris-HCl, pH 8.0, with 0.1% BSA and 1 mM EDTA) at 37°C. The reaction is monitored fluorometrically (excitation 360 nm, emission 460 nm). IC₅₀ values are calculated from concentration-response curves. Selectivity profiling against other serine hydrolases may be performed to confirm specificity. These protocols are for reference only and require independent validation.
|
| Cell Assay |
In vitro cellular experiments with N-(3-Methoxybenzyl)Palmitamide are performed using various cell lines to assess FAAH inhibition and its biological consequences. Cells such as neuronal cell lines, microglia, or FAAH-expressing cell lines are cultured in appropriate media and treated with varying concentrations of the compound for 24-72 hours. FAAH activity in cell lysates is measured using fluorogenic substrates. The compound's effects on fatty acid amide levels (e.g., anandamide, oleamide) are quantified by LC-MS. Cellular responses including cytokine production, calcium mobilization, and cell viability are assessed to evaluate the functional consequences of FAAH inhibition. Cells are maintained at 37°C in 5% CO₂ with appropriate media supplements.
|
| Animal Protocol |
In vivo animal studies with N-(3-Methoxybenzyl)Palmitamide have not been extensively reported in the literature. As an FAAH inhibitor, standard in vivo models for evaluating analgesic, anti-inflammatory, and neuroprotective effects include rodent models of pain (e.g., formalin test, tail-flick test, neuropathic pain models), inflammation (e.g., carrageenan-induced paw edema), and neurodegeneration (e.g., MPTP model for Parkinson's disease). Animals are typically treated with the compound via oral, intraperitoneal, or intravenous administration at various doses. Efficacy is assessed by measuring pain responses, inflammatory markers, or neurobehavioral outcomes. Pharmacodynamic markers such as brain fatty acid amide levels may be measured to confirm target engagement. The compound shows promise for treating pain, inflammation, and CNS degenerative disorders.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of N-(3-Methoxybenzyl)Palmitamide are not extensively characterized. The compound has molecular formula C₂₄H₄₁NO₂ and molecular weight 375.59 g/mol. It appears as a white to off-white solid powder with a LogP of 8.3, indicating high lipophilicity. The predicted boiling point is 532.1±33.0°C and density is 0.939±0.06 g/cm³. The pKa is predicted at 15.78±0.46. Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month. The compound should be stored in a sealed environment protected from moisture and light. Solubility may be achieved in DMSO.
|
| Toxicity/Toxicokinetics |
Toxicological information for N-(3-Methoxybenzyl)Palmitamide indicates that the compound has hazard statements H302 (Harmful if swallowed), H315 (Causes skin irritation), H319 (Causes serious eye irritation), and H335 (May cause respiratory irritation). Precautionary statements include P261 (Avoid breathing dust/fume/gas/mist/vapors/spray) and P305+P351+P338 (IF IN EYES: Rinse cautiously with water for several minutes; remove contact lenses if present and easy to do; continue rinsing). The signal word is "Warning". As a research compound with FAAH inhibitory activity, it should be handled with appropriate safety precautions including personal protective equipment (gloves, safety goggles, lab coat) and working in a well-ventilated area. The compound is for research use only and is not approved for human therapeutic use.
|
| References | |
| Additional Infomation |
According to reports, Lepidium meyenii contains N-(3-methoxybenzyl)palmitamide, and relevant data is available.
N-(3-Methoxybenzyl)Palmitamide (CAS 847361-96-0) is a promising inhibitor of fatty acid amide hydrolase (FAAH) for the treatment of pain, inflammation, and CNS degenerative disorders. The compound has molecular formula C₂₄H₄₁NO₂ and molecular weight 375.59 g/mol. It appears as a white to off-white solid powder and has been reported in Lepidium meyenii (maca). The compound is also known as Macamide Impurity 5 and N-(3-methoxybenzyl)-hexadecanamide. Purity is ≥98%. Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month. The compound is for research use only and is not for human use. |
| Molecular Formula |
C24H41NO2
|
|---|---|
| Molecular Weight |
375.587847471237
|
| Exact Mass |
375.313
|
| CAS # |
847361-96-0
|
| PubChem CID |
71765531
|
| Appearance |
White to off-white solid powder
|
| LogP |
8.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
27
|
| Complexity |
345
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(CCCCCCCCCCCCCCC)NCC1C=C(OC)C=CC=1
|
| InChi Key |
FIQGQTITXPTKIY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H41NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-19-24(26)25-21-22-17-16-18-23(20-22)27-2/h16-18,20H,3-15,19,21H2,1-2H3,(H,25,26)
|
| Chemical Name |
N-[(3-methoxyphenyl)methyl]hexadecanamide
|
| Synonyms |
N(3Methoxybenzyl)Palmitamide; N (3 Methoxybenzyl)Palmitamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6625 mL | 13.3124 mL | 26.6248 mL | |
| 5 mM | 0.5325 mL | 2.6625 mL | 5.3250 mL | |
| 10 mM | 0.2662 mL | 1.3312 mL | 2.6625 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
